196 related articles for article (PubMed ID: 34056541)
1. Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study.
Höppener DJ; Galjart B; Nierop PMH; Buisman FE; van der Stok EP; Coebergh van den Braak RRJ; van Amerongen MJ; Balachandran VP; Jarnagin WR; Kingham TP; Doukas M; Shia J; Nagtegaal ID; Vermeulen PB; Koerkamp BG; Grünhagen DJ; de Wilt JHW; D'Angelica MI; Verhoef C
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056541
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
3. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases.
Buisman FE; van der Stok EP; Galjart B; Vermeulen PB; Balachandran VP; Coebergh van den Braak RRJ; Creasy JM; Höppener DJ; Jarnagin WR; Kingham TP; Nierop PMH; Sadot E; Shia J; Groot Koerkamp B; Grünhagen DJ; D'Angelica M; Verhoef C
Clin Exp Metastasis; 2020 Oct; 37(5):593-605. PubMed ID: 32691187
[TBL] [Abstract][Full Text] [Related]
4. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
5. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
8. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.
Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ
Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
[TBL] [Abstract][Full Text] [Related]
11. Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study.
Chang W; Chen Y; Zhou S; Ren L; Xu Y; Zhu D; Tang W; Ye Q; Wang X; Fan J; Wei Y; Xu J
Int J Surg; 2023 Oct; 109(10):3070-3077. PubMed ID: 37526097
[TBL] [Abstract][Full Text] [Related]
12. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
13. Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
Buisman FE; Giardiello D; Kemeny NE; Steyerberg EW; Höppener DJ; Galjart B; Nierop PMH; Balachandran VP; Cercek A; Drebin JA; Gönen M; Jarnagin WR; Kingham TP; Vermeulen PB; Wei AC; Grünhagen DJ; Verhoef C; D'Angelica MI; Koerkamp BG
Eur J Cancer; 2022 Jun; 168():25-33. PubMed ID: 35430383
[TBL] [Abstract][Full Text] [Related]
14. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
[TBL] [Abstract][Full Text] [Related]
15. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
Nierop PM; Höppener DJ; Buisman FE; van der Stok EP; Galjart B; Balachandran VP; Jarnagin WR; Kingham TP; Shia J; Mauer M; Nordlinger B; Julié C; Groot Koerkamp B; Doukas M; Vermeulen PB; Grünhagen DJ; D'Angelica MI; Verhoef C
J Pathol Clin Res; 2022 Jan; 8(1):48-64. PubMed ID: 34480530
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
17. Histopathological growth patterns of resected non-colorectal, non-neuroendocrine liver metastases: a retrospective multicenter study.
Meyer Y; Bohlok A; Höppener D; Galjart B; Doukas M; Grünhagen DJ; Labar A; Lucidi V; Vermeulen PB; Verhoef C; Donckier V
Clin Exp Metastasis; 2022 Jun; 39(3):433-442. PubMed ID: 35124739
[TBL] [Abstract][Full Text] [Related]
18. The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis.
Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Galjart B; Kamphues C; Pawlik TM; Poultsides G; Kaczirek K; Lønning PE; Verhoef C; Kreis ME; Wolfgang CL; Weiss MJ
J Surg Oncol; 2018 Dec; 118(7):1074-1080. PubMed ID: 30261094
[TBL] [Abstract][Full Text] [Related]
19. Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns.
Nierop PMH; Galjart B; Höppener DJ; van der Stok EP; Coebergh van den Braak RRJ; Vermeulen PB; Grünhagen DJ; Verhoef C
Clin Exp Metastasis; 2019 Apr; 36(2):109-118. PubMed ID: 30843120
[TBL] [Abstract][Full Text] [Related]
20. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
